Other than the tumor PD-L1 expression in the first-line ICI use in non-small cell lung cancer (NSCLC) and tumor agnostic use of tumor mutational burden (TMB) and microsatellite instability (MSI), no other biomarker has entered routine clinical use [13,14,15]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.